



WHAT IS CLAIMED IS:


1. A compound of formula (I):-



5 such that Ar is an aryl group or a heteroaryl group, and the



group on the aryl,



group is beta to the

wherein:-

— — — is a single or a double bond;

10 R¹ and R² are each independently hydrogen or lower alkyl;

R³ is aryl, arylalkenyl, cycloalkenyl, cycloalkyl, heteroaryl, heteroarylalkenyl, heterocycloalkenyl, a carbon linked heterocycloalkyl or alkyl optionally substituted by one or more groups selected from hydroxy, alkoxy, alkyloxycarbonylamino, cycloalkyl, heterocycloalkyl, R⁶, -OR⁶, -S(O)_mR⁶ or -C(=O)-R⁶;

15 R⁴ is hydrogen, acyl, alkoxy, alkyloxycarbonyl, carboxy, cyano, halo, hydroxy, -C(=O)-NY¹Y² or alkyl optionally substituted with alkoxy, alkylcarbonylamino, alkylsulfonylamino, hydroxy, -S(O)_m-alkyl or -NY¹Y²;

R⁵ is hydrogen, acyl, alkoxy, alkyloxycarbonyl, aryl, carboxy, cyano, halo, heteroaryl, heteroaryloxy, heterocycloalkyl, heterocycloalkyloxy, heterocycloalkylalkyloxy, heteroarylalkyloxy, hydroxy,

20 trifluoromethyl, -C(=O)-NY¹Y², -NY¹Y², -Z¹-C₂₋₆alkylene-R⁷ or alkyl optionally substituted with alkoxy, alkylcarbonylamino, alkylsulfonylamino, aryl, heteroaryl, heterocycloalkyl, hydroxy, ureido, -C(=O)-NY¹Y², -SO₂-NY¹Y², -S(O)_m-alkyl or -NY¹Y²;

R⁶ is aryl or heteroaryl;

R⁷ is hydroxy, alkoxy, ureido, -C(=O)-NY¹Y², -SO₂-NY¹Y², -S(O)_m-alkyl or -NY¹Y²;

R⁸ is hydrogen or lower alkyl;

Y¹ and Y² are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl,

heteroaryalkyl or heterocycloalkyl; or the group -NY¹Y² may form a cyclic amine;

Z¹ is O, S(O)_m or NR⁸;

5 m is zero or an integer 1 to 2;

n is zero or an integer 1 to 4;

an N-oxide of said compound, a prodrug of said compound, a pharmaceutically acceptable salt of said compound, a solvate of said compound, and a hydrate of said compound.

10 2. The compound of Claim 1, wherein R¹ and/or R² is hydrogen, and R³ is an aryl or an heteroaryl.

3. The compound of Claim 2, wherein said R³ aryl comprises a phenyl or a naphthyl.

15 4. The compound of Claim 2, wherein said R³ aryl is substituted with at least one substituent.

5. The compound of Claim 4, wherein said substituent is selected from the group consisting of a halo atom, an alkyl substituted by aryl, an alkyl substituted by aryloxy, an alkyl substituted by aroyl, an alkyl substituted by heteroaryl, an arylalkynyl, a heteroarylalkynyl, an aryl, a heteroaryl, an arylalkenyl and an arylalkyloxy.

20 6. The compound of Claim 5, wherein said aryl or heteroaryl of said substituent is further substituted by at least one aryl group substituent.

25 7. The compound of Claim 2, wherein said heteroaryl comprises a pyridyl, a quinolinyl, a thienyl, a furanyl, or an indolyl.

8. The compound of Claim 7, wherein said heteroaryl is substituted with at least one substituent.

30 9. The compound of Claim 8, wherein said substituent comprises an alkyl, an alkyl substituted by an aryl, an alkyl substituted by an aryloxy, an alkyl substituted by an aroyl, an alkyl substituted heteroaryl, an arylalkynyl, a heteroarylalkynyl, a heteroaryl, an arylalkenyl or an arylalkyloxy.


35 10. The compound of Claim 9, wherein said aryl of said substituent is further substituted by at least one aryl substituent.

11. The compound of Claim 1, wherein R⁴ comprises hydrogen or a cyano group.
12. The compound of Claim 1, wherein R⁵ comprises a hydrogen, a lower alkyl, or a halo.
- 5 13. The compound of Claim 1, wherein is a single bond.
14. The compound of Claim 1, wherein n=2.
- 10 15. The compound of Claim 1, wherein:
Ar comprises a phenyl group;
R¹=R²=hydrogen;
R³ comprises an aryl, a naphthyl, or a heteroaryl;
R⁴ comprises hydrogen or a cyano group;
15 R⁵ comprises hydrogen, a lower alkyl, or a halo;
 represents a single bond; and
n=2.
16. The compound of Claim 15, wherein said aryl or said naphthyl of R³ is substituted with at least one substituent comprising a halo atom, an alkyl substituted by aryl, an alkyl substituted by aryloxy, an alkyl substituted by aroyl, an alkyl substituted by aryloxy, an alkyl substituted by aroyl, an alkyl substituted by a heteroaryl, an arylalkynyl, a heteroarylalkynyl, an aryl, a heteroaryl, an arylalkenyl, or an arylalkyloxy.
- 20 17. The compound of Claim 16, wherein said aryl or said heteroaryl of said substituent is further substituted by at least one aryl substituent.
- 25 18. The compound of Claim 15, wherein said heteroaryl of R³ is substituted by at least one substituent comprising a pyridyl, a quinolinyl, a thienyl a furanyl, or an indolyl.
- 30 19. The compound of Claim 18, wherein said substituent of said heteroaryl is further substituted by at least one moiety comprising an alkyl substituted by an aryl, an alkyl substituted by an aryloxy, an alkyl substituted by an aroyl, an alkyl substituted heteroaryl, an arylalkynyl, a heteroarylalkynyl, a heteroaryl, an arylalkenyl, or an arylalkyloxy.

20. The compound of Claim 19, wherein an aryl of said moiety is further substituted by at least one aryl substituent.

21. A compound of formula (Ia):

5



wherein

R³ is aryl, arylalkenyl, cycloalkenyl, cycloalkyl, heteroaryl, heteroarylalkenyl, heterocycloalkenyl, a 10 carbon linked heterocycloalkyl or alkyl optionally substituted by one or more groups selected from hydroxy, alkoxy, alkyloxycarbonylamino, cycloalkyl, heterocycloalkyl, R⁶, -OR⁶, -S(O)mR⁶ or -C(=O)-R⁶;

R⁴ is hydrogen, acyl, alkoxy, alkyloxycarbonyl, carboxy, cyano, halo, hydroxy, -C(=O)-NY¹Y² or alkyl optionally substituted with alkoxy, alkylcarbonylamino, alkylsulfonylamino, hydroxy, 15 -S(O)m-alkyl or -NY¹Y²; and

R⁵ is hydrogen, acyl, alkoxy, alkyloxycarbonyl, aryl, carboxy, cyano, halo, heteroaryl, heteroaryloxy, heterocycloalkyl, heterocycloalkyloxy, heterocycloalkylalkyloxy, heteroarylalkyloxy, hydroxy, trifluoromethyl, -C(=O)-NY¹Y², -NY¹Y², -Z¹-C₂₋₆alkylene-R⁷ or alkyl optionally substituted with alkoxy, alkylcarbonylamino, alkylsulfonylamino, aryl, heteroaryl, heterocycloalkyl, hydroxy, ureido, 20 -C(=O)-NY¹Y², -SO₂-NY¹Y², -S(O)m-alkyl or -NY¹Y², and,

a corresponding N-oxide of said compound, a prodrug of said compound, a pharmaceutically acceptable salt of said compound, a solvate of said compound, an N-oxides and prodrugs.

22. The compound of Claim 21, wherein R³ is an aryl comprising a phenyl or a naphthyl.
23. The compound of Claim 22, wherein said aryl is substituted by at least one substituent comprising a halo atom, an alkyl substituted by an aryl, an alkyl substituted by a heteroaryl.
5
24. The compound of Claim 23, wherein said aryl or heteroaryl of said substituent is further substituted by at least one aryl group substituent.
25. The compound of Claim 21, wherein R³ comprises phenylC₁₋₃alkylpyridyl [e.g. 5-phenylethyl-pyrid-3-yl], phenylC₁₋₃alkylthienyl [e.g. 5-phenylethyl-thien-2-yl] or indolyl [e.g. indol-6-yl].
10
26. The compound of Claim 21, wherein R³ is a heteroaryl comprising a pyridyl, a quinolinyl, a thienyl, a furanyl, or an indolyl.
15
27. The compound of Claim 26, wherein said heteroaryl is substituted by at least one substituent comprising an alkyl substituted by an aryl, or an alkyl substituted by a heteroaryl.
28. The compound of Claim 27, wherein said aryl and said heteroaryl of said substituent are further substituted by at least one aryl group substituent.
20
29. The compound of Claim 28, wherein R³ comprises phenylC₁₋₃alkylpyridyl [e.g. 5-phenylethyl-pyrid-3-yl], phenylC₁₋₃alkylthienyl [e.g. 5-phenylethyl-thien-2-yl], or indolyl [e.g. indol-6-yl].
25
30. The compound of Claim 21, wherein R⁴ comprises a hydrogen or a cyano.
31. The compound of Claim 21, wherein R⁵ comprises a hydrogen, a lower alkyl or a halo.
30
32. The compound of Claim 31, wherein R⁵ comprises a methyl or a fluoro.
33. The compound of Claim 31, wherein R⁵ is attached to the phenyl ring of formula (Ia) in the position para to the CH₂NH₂ group.
- 35 34. The compound of Claim 21, wherein:

R^3 is a phenyl, a naphthyl, a heteroaryl selected from the group consisting a pyridyl, a quinolinyl, a thienyl, a furanyl, and an indolyl, a phenyl substituted by at least one substituent, a naphthyl substituted by at least one substituent, or a heteroaryl selected from the group consisting a pyridyl, a quinolinyl, a thienyl, a furanyl, and an indolyl, that is substituted by at least one substituent,

5 wherein said substituent is selected from the group consisting of a halo atom, an alkyl substituted by aryl, and alkyl substituted heteroaryl, wherein the aryl or heteroaryl groups are further substituted by one or more aryl group substituents;

R^4 comprises hydrogen or a cyano; and

R^5 comprises hydrogen, a lower alkyl or a halo.

10


35. The compound of Claim 34, wherein:

R^3 comprises phenylC₁₋₃alkylpyridyl [e.g. 5-phenylethyl-pyrid-3-yl], phenylC₁₋₃alkylthienyl [e.g. 5-phenylethyl-thien-2-yl] or indolyl [e.g. indol-6-yl];

R^4 comprises a hydrogen or a cyano; and

15 R^5 comprises a methyl or a fluoro, and is attached to the phenyl ring of formula (Ib) in the position para to the CH₂NH₂ group.

36. A compound of formula (Ib):



20

wherein

R^3 is aryl, arylalkenyl, cycloalkenyl, cycloalkyl, heteroaryl, heteroarylalkenyl, heterocycloalkenyl, a carbon linked heterocycloalkyl or alkyl optionally substituted by one or more groups selected from hydroxy, alkoxy, alkyloxycarbonylamino, cycloalkyl, heterocycloalkyl, R⁶, -OR⁶, -S(O)_mR⁶ or

-C(=O)-R⁶;

25 R^4 is hydrogen, acyl, alkoxy, alkyloxycarbonyl, carboxy, cyano, halo, hydroxy, -C(=O)-NY¹Y² or alkyl optionally substituted with alkoxy, alkylcarbonylamino, alkylsulfonylamino, hydroxy, -S(O)_m-alkyl or -NY¹Y²; and

R⁵ is hydrogen, acyl, alkoxy, alkyloxycarbonyl, aryl, carboxy, cyano, halo, heteroaryl, heteroaryloxy, heterocycloalkyl, heterocycloalkyloxy, heterocycloalkylalkyloxy, heteroarylalkyloxy, hydroxy, trifluoromethyl, -C(=O)-NY¹Y², -NY¹Y², -Z¹-C₂₋₆alkylene-R⁷ or alkyl optionally substituted with alkoxy, alkylcarbonylamino, alkylsulfonylamino, aryl, heteroaryl, heterocycloalkyl, hydroxy, ureido, 5 -C(=O)-NY¹Y², -SO₂-NY¹Y², -S(O)_m-alkyl or -NY¹Y², and, a corresponding N-oxide of said compound, a prodrug of said compound, a pharmaceutically acceptable salt of said compound, a solvate of said compound, an N-oxides and prodrugs.

37. The compound of Claim 36, wherein R³ is an aryl comprising a phenyl or a naphthyl.

10

38. The compound of Claim 37, wherein said aryl is substituted by at least one substituent comprising a halo atom, an alkyl substituted by an aryl, an alkyl substituted by a heteroaryl.

15

39. The compound of Claim 38, wherein said aryl or heteroaryl of said substituent is further substituted by at least one aryl group substituent.

40. The compound of Claim 36, wherein R³ is a heteroaryl comprising a pyridyl, a quinolinyl, a thienyl, a furanyl, or an indolyl.

20

41. The compound of Claim 41, wherein said heteroaryl is substituted by at least one substituent comprising an alkyl substituted by an aryl, or an alkyl substituted by a heteroaryl.

42. The compound of Claim 42, wherein said aryl and said heteroaryl of said substituent are further substituted by at least one aryl group substituent.

25

43. The compound of Claim 36, wherein R³ comprises phenylC₁₋₃alkylpyridyl [e.g. 5-phenylethyl-pyrid-3-yl], phenylC₁₋₃alkylthienyl [e.g. 5-phenylethyl-thien-2-yl], or indolyl [e.g. indol-6-yl].

44. The compound of Claim 36, wherein R⁴ comprises a hydrogen or a cyano.

30

45. The compound of Claim 36, wherein R⁵ comprises a hydrogen, a lower alkyl or a halo.

46. The compound of Claim 45, wherein R⁵ comprises a methyl or a fluoro.

47. The compound of Claim 45, wherein R⁵ is attached to the phenyl ring of formula (Ib) in the position para to the CH₂NH₂ group.

48. The compound of Claim 36, wherein:

R³ is a phenyl, a naphthyl, a heteroaryl selected from the group consisting a pyridyl, a quinolinyl, a thienyl, a furanyl, and an indolyl, a phenyl substituted by at least one substituent, a naphthyl substituted by at least one substituent, or a heteroaryl selected from the group consisting a pyridyl, a quinolinyl, a thienyl, a furanyl, and an indolyl, that is substituted by at least one substituent, wherein said substituent is selected from the group consisting of a halo atom, an alkyl substituted by aryl, and alkyl substituted heteroaryl, wherein the aryl or heteroaryl groups are further substituted by one or more aryl group substituents;

R⁴ comprises hydrogen or a cyano; and

R⁵ comprises hydrogen, a lower alkyl or a halo.

49. The compound of Claim 48, wherein:

R³ comprises phenylC₁₋₃alkylpyridyl [e.g. 5-phenylethyl-pyrid-3-yl], phenylC₁₋₃alkylthienyl [e.g. 5-phenylethyl-thien-2-yl] or indolyl [e.g. indol-6-yl];

R⁴ comprises a hydrogen or a cyano; and

R⁵ comprises a methyl or a fluoro, and is attached to the phenyl ring of formula (Ib) in the position para to the CH₂NH₂ group.

50. The compound of Claim 1, selected from the group consisting of:

3-[1-(5-phenylethynyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine;

3-[1-(3-phenylethyl-benzoyl)-piperidin-4-yl]-benzylamine;

3-{1-[3-(4-hydroxyphenyl)ethyl-benzoyl]-piperidin-4-yl}-benzylamine;

3-{1-[3-(6-amino-pyridin-3-yl)ethyl-benzoyl]-piperidin-4-yl}-benzylamine;

3-[1-(5-phenylethyl-thiophene-2-carbonyl)-piperidin-4-yl]-benzylamine;

4-fluoro-3-[1-(5-phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine;

4-methyl-3-[1-(5-phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine;

3-[1-(indole-6-carbonyl)-piperidin-4-yl]-benzylamine;

4-(3-aminomethyl-phenyl)-1-(5-phenethyl-pyridine-3-carbonyl)-piperidine-4-carbonitrile

[4-(3-aminomethylphenyl)piperidin-1-yl]-(3,4-dichlorophenyl)methanone;

1-[1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-methanoyl]-3-methylsulfanyl-6,7-dihydro-5H-benzo[c]thiophen-4-one trifluoroacetate;

1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(3-methylsulfanyl-6,7-dihydro-benzo[c]thiophen-1-yl)-methanone trifluoroacetate;

- 1-{1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-methanoyl}-3-ethylsulfanyl-6,6-dimethyl-6,7-dihydro-5H-benzo[c]thiophen-4-one trifluoroacetate;
- 1-{1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-methanoyl}-3-propylsulfanyl-6,7-dihydro-5H-benzo[c]thiophen-4-one trifluoroacetate;
- 5 1-{1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-methanoyl}-3-isopropylsulfanyl-6,7-dihydro-5H-benzo[c]thiophen-4-one trifluoroacetate;
- 1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-benzo[b]thiophen-2-yl-methanone-trifluoroacetate;
- 1-[4-(3-Aminomethyl-phenyl)-4-hydroxy-piperidin-1-yl]-1-(5-phenethyl-pyridin-3-yl)-methanone-ditrifluoroacetate;
- 10 1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(1-methyl-1H-indol-3-yl)-methanone-trifluoroacetate;
- 1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-[3-(2-fluoro-phenylethynyl)-phenyl]-methanone trifluoroacetate;
- 1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-{3-[2-(2-fluoro-phenyl)-ethyl]-phenyl}-methanone trifluoroacetate;
- 15 1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-{3-[2-(6-amino-pyridin-3-yl)-ethyl]-phenyl}-methanone tri-trifluoroacetate;
- 1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(6-chloro-thieno[3,2-*b*]thiophen-2-yl)-methanone trifluoroacetate;
- (3R,4S) and (3S, 4R)-4-(3-Aminomethyl-phenyl)-1-(5-phenethyl-pyridine-3-carbonyl)-piperidine-3-
- 20 carboxylic acid ethyl ester dihydrochloride;
- 3-[1-(5-Phenylethynyl-furan-2-carbonyl)-piperidin-4-yl]-benzylamine trifluoroacetate;
- 4-(3-Aminomethyl-phenyl)-piperidine-1-carboxylic acid (3,4-dichloro-phenyl)-amide trifluoroacetate;
- 1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(2,3-dihydro-benzofuran-5-yl)-methanone;
- 1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(5,6-dichloro-pyridin-3-yl)-methanone;
- 25 1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(3-bromo-4-fluoro-phenyl)-methanone;
- (E)-1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-3-(2-nitro-phenyl)-propenone;
- 1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(3-bromo-5-iodo-phenyl)-methanone; and
- (E)-1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-3-phenyl-propenone.
- 30 51. A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier thereof.
52. The pharmaceutical composition of Claim 51, wherein said compound is selected from the group consisting of:
- 35 3-[1-(5-phenylethynyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine;
- 3-[1-(3-phenylethyl-benzoyl)-piperidin-4-yl]-benzylamine;

- 3-[1-[3-(4-hydroxyphenyl)ethyl-benzoyl]-piperidin-4-yl]-benzylamine;
3-[1-[3-(6-amino-pyridin-3-yl)ethyl-benzoyl]-piperidin-4-yl]-benzylamine;
3-[1-(5-phenylethyl-thiophene-2-carbonyl)-piperidin-4-yl]-benzylamine;
4-fluoro-3-[1-(5-phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine;
5 4-methyl-3-[1-(5-phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine;
3-[1-(indole-6-carbonyl)-piperidin-4-yl]-benzylamine;
4-(3-aminomethyl-phenyl)-1-(5-phenethyl-pyridine-3-carbonyl)-piperidine-4-carbonitrile
[4-(3-aminomethylphenyl)piperidin-1-yl]-(3,4-dichlorophenyl)methanone;
1-[1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-methanoyl]-3-methylsulfanyl-6,7-dihydro-5H-
10 benzo[c]thiophen-4-one trifluoroacetate;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(3-methylsulfanyl-6,7-dihydro-benzo[c]thiophen-1-
yl)-methanone trifluoroacetate;
1-[1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-methanoyl]-3-ethylsulfanyl-6,6-dimethyl-6,7-
dihydro-5H-benzo[c]thiophen-4-one trifluoroacetate;
15 1-[1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-methanoyl]-3-propylsulfanyl-6,7-dihydro-5H-
benzo[c]thiophen-4-one trifluoroacetate;
1-[1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-methanoyl]-3-isopropylsulfanyl-6,7-dihydro-5H-
benzo[c]thiophen-4-one trifluoroacetate;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-benzo[b]thiophen-2-yl-methanone-trifluoroacetate;
20 1-[4-(3-Aminomethyl-phenyl)-4-hydroxy-piperidin-1-yl]-1-(5-phenethyl-pyridin-3-yl)-methanone-
ditrifluoroacetate;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(1-methyl-1H-indol-3-yl)-methanone-trifluoroacetate;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-[3-(2-fluoro-phenylethynyl)-phenyl]-methanone
trifluoroacetate;
25 1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-[3-[2-(2-fluoro-phenyl)-ethyl]-phenyl]-methanone
trifluoroacetate;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-[3-[2-(6-amino-pyridin-3-yl)-ethyl]-phenyl]-
methanone tri-trifluoroacetate;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(6-chloro-thieno[3,2-*b*]thiophen-2-yl)-methanone
30 trifluoroacetate;
(3R,4S) and (3S, 4R)-4-(3-Aminomethyl-phenyl)-1-(5-phenethyl-pyridine-3-carbonyl)-piperidine-3-
carboxylic acid ethyl ester dihydrochloride;
3-[1-(5-Phenylethynyl-furan-2-carbonyl)-piperidin-4-yl]-benzylamine trifluoroacetate;
4-(3-Aminomethyl-phenyl)-piperidine-1-carboxylic acid (3,4-dichloro-phenyl)-amide trifluoroacetate;
35 1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(2,3-dihydro-benzofuran-5-yl)-methanone;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(5,6-dichloro-pyridin-3-yl)-methanone;

1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(3-bromo-4-fluoro-phenyl)-methanone;
(E)-1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-3-(2-nitro-phenyl)-propenone;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(3-bromo-5-iodo-phenyl)-methanone;
(E)-1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-3-phenyl-propenone; and
5 1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-3-cyclohexyl-propan-1-one.

53. A pharmaceutical composition comprising a compound of Claim 21 and a pharmaceutically acceptable carrier thereof.

10 54. A pharmaceutical composition comprising a compound of Claim 36 and a pharmaceutically acceptable carrier thereof.

15 55. A method for treating a patient suffering from, or subject to, a condition that can be ameliorated by the administration of an inhibitor of tryptase, wherein the method comprises administering to the patient an effective amount of a compound of Claim 1.

20 56. The method of Claim 55, wherein the condition comprises inflammatory disease, a disease of joint cartilage destruction, ocular conjunctivitis, vernal conjunctivitis, inflammatory bowel disease, asthma, allergic rhinitis, an interstitial lung disease, fibrosis, scleroderma, pulmonary fibrosis, liver cirrhosis, myocardial fibrosis, a neurofibroma, a hypertrophic scar, a dermatological condition, a condition related to atherosclerotic plaque rupture, periodontal disease, diabetic retinopathy, tumor growth, anaphylaxis, multiple sclerosis, a peptic ulcer, or a syncytial viral infection.

25 57. The method of Claim 56, wherein the inflammatory disease comprises joint inflammation, arthritis, rheumatoid arthritis, rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis, or osteoarthritis; the dermatological condition comprises atopic dermatitis or psoriasis; and the condition related to atherosclerotic plaque rupture comprises myocardial infarction, stroke, or angina.

30 58. A method for treating a patient suffering from, or subject to, a condition that can be ameliorated by the administration of an inhibitor of tryptase, wherein the method comprises administering to the patient an effective amount of a compound of Claim 21.

59. The method of Claim 58, wherein the condition comprises inflammatory disease, a disease of joint cartilage destruction, ocular conjunctivitis, vernal conjunctivitis, inflammatory bowel disease, asthma, allergic rhinitis, an interstitial lung disease, fibrosis, scleroderma, pulmonary fibrosis, liver cirrhosis, myocardial fibrosis, a neurofibroma, a hypertrophic scar, a dermatological condition, a condition related to atherosclerotic plaque rupture, periodontal disease, diabetic retinopathy, tumor growth, anaphylaxis, multiple sclerosis, a peptic ulcer, or a syncytial viral infection.
60. The method of Claim 59, wherein the inflammatory disease comprises joint inflammation, arthritis, rheumatoid arthritis, rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis, or osteoarthritis; the dermatological condition comprises atopic dermatitis or psoriasis; and the condition related to atherosclerotic plaque rupture comprises myocardial infarction, stroke, or angina.
- 15 61. A method for treating a patient suffering from, or subject to, a condition that can be ameliorated by the administration of an inhibitor of tryptase, wherein the method comprises administering to the patient an effective amount of a compound of Claim 36.
- 20 62. The method of Claim 61, wherein the condition comprises inflammatory disease, a disease of joint cartilage destruction, ocular conjunctivitis, vernal conjunctivitis, inflammatory bowel disease, asthma, allergic rhinitis, an interstitial lung disease, fibrosis, scleroderma, pulmonary fibrosis, liver cirrhosis, myocardial fibrosis, a neurofibroma, a hypertrophic scar, a dermatological condition, a condition related to atherosclerotic plaque rupture, periodontal disease, diabetic retinopathy, tumor growth, anaphylaxis, multiple sclerosis, a peptic ulcer, or a syncytial viral infection.
- 25 63. The method of Claim 62, wherein the inflammatory disease comprises joint inflammation, arthritis, rheumatoid arthritis, rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis, or osteoarthritis; the dermatological condition comprises atopic dermatitis or psoriasis; and the condition related to atherosclerotic plaque rupture comprises myocardial infarction, stroke, or angina.
- 30 64. A pharmaceutical composition comprising a compound of Claim 1 and a second compound selected from the group consisting of a beta adrenergic agonist, an anticholinergic, an anti-

inflammatory corticosteroid, and an anti-inflammatory agent; and a pharmaceutically acceptable carrier thereof.

65. The pharmaceutical composition of Claim 64, wherein the beta adrenergic agonist comprises
5 albuterol, terbutaline, formoterol, fenoterol or prenalone;
the anticholinergic comprises ipratropium bromide;
the anti-inflammatory corticosteroid comprises beclomethasone dipropionate, triamcinolone acetonide, flunisolide or dexamethasone; and
the anti-inflammatory agent comprises sodium cromoglycate or nedocromil sodium.
- 10 66. A pharmaceutical composition comprising a compound of formula 21 and a second compound selected from the group consisting of a beta adrenergic agonist, an anticholinergic, an anti-inflammatory corticosteroid, and an anti-inflammatory agent; and a pharmaceutically acceptable carrier thereof.
- 15 67. The pharmaceutical composition of Claim 66, wherein the beta adrenergic agonist comprises albuterol, terbutaline, formoterol, fenoterol or prenalone;
the anticholinergic comprises ipratropium bromide;
the anti-inflammatory corticosteroid comprises beclomethasone dipropionate, triamcinolone acetonide, flunisolide or dexamethasone; and
20 the anti-inflammatory agent comprises sodium cromoglycate or nedocromil sodium.
- 25 68. A pharmaceutical composition comprising a compound Claim 36 and a second compound selected from the group consisting of a beta adrenergic agonist, an anticholinergic, an anti-inflammatory corticosteroid, and an anti-inflammatory agent; and a pharmaceutically acceptable carrier thereof.
69. The pharmaceutical composition of Claim 66, wherein the beta adrenergic agonist comprises albuterol, terbutaline, formoterol, fenoterol or prenalone;
the anticholinergic comprises ipratropium bromide;
30 the anti-inflammatory corticosteroid comprises beclomethasone dipropionate, triamcinolone acetonide, flunisolide or dexamethasone; and
the anti-inflammatory agent comprises sodium cromoglycate or nedocromil sodium.
70. A method for treating a patient suffering from asthma, comprising administering to the patient
35 a combination of a compound of Claim 1, and a second compound selected from the group

consisting of a beta adrenergic agonist, an anticholinergic, an anti-inflammatory corticosteroid, and an anti-inflammatory agent

71. A method for treating a patient suffering from asthma, comprising administering to the patient
5 a combination of a compound of Claim 21, and a second compound selected from the group consisting of a beta adrenergic agonist, an anticholinergic, an anti-inflammatory corticosteroid, and an anti-inflammatory agent.
72. A method for treating a patient suffering from asthma, comprising administering to the patient
10 a combination of a compound of Claim 36, and a second compound selected from the group consisting of a beta adrenergic agonist, an anticholinergic, an anti-inflammatory corticosteroid, and an anti-inflammatory agent.